Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation
Andrew J Shepherd, Andrew SC Rice, Maree T Smith · 2023
Read Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation by Andrew J Shepherd, Andrew SC Rice, Maree T Smith (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11789660.txt.
Description
Andrew Shepherd, Andrew Rice, and Maree Smith trace a pain drug's path from lab to clinic and back in a 2023 paper. Their target is the angiotensin II type 2 receptor, a lesser-known cousin of a famous blood pressure receptor. Blockers of this receptor eased nerve pain in rodents, earning a human trial.
The trial, in patients with shingles-related nerve pain, gave positive proof of concept. The chosen drug, EMA401, was picked for its clean safety profile and good behavior in the body. The paper reviews the target's discovery, the animal work, and the clinical development. It uses the story to show how back-translation, checking clinic results against lab models, can guide pain drug hunting.
Catalog record
| CREATOR | Andrew J Shepherd, Andrew SC Rice, Maree T Smith |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |